North China Pharmaceutical completes clinical trials on recombinant human serum albumin

The studies were started in 2011 and were completed by the end of 2013. The use of HAS will be as a component of vaccines or pharmaceutical excipients.

China Bio news release, July 29, 2014

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny